International Journal of Endocrinology and Metabolism
Research Institute for Endocrine Sciences
Scopus by Title (Ref)
Articles that cite the referenced work, matched by title from the Scopus database.
Efficacy of dapagliflozin on hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a pre-specified single-arm analysis from a randomized controlled trial
Diabetes Research and Clinical Practice
October 2026
Sambit D.
Neuropsychiatric adverse events of SGLT2 inhibitors: a pharmacovigilance analysis of the FDA adverse event reporting system database
Frontiers in Medicine
29 May 2026
Yin M.
Efficacy and Safety of Dapagliflozin in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fractions: A Systematic Review and Meta-Analysis
Journal of the Nepal Medical Association
April 2026
Duwadi B.
SGLT2 Inhibitors and Long-Term Outcomes After AKI
Kidney International Reports
March 2026
Wannakittirat A.
Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy
Acta Diabetologica
March 2026
Soyaltin U.
rs10010131A in WFS1 is Associated with Elevated Serum Urea in Type 2 Diabetes Patients Treated with SGLT2 Inhibitors
Therapeutics and Clinical Risk Management
2026
Naja K.
SGLT2-inhibition and myocardial infarction size in patients with type 2 diabetes mellitus– Insights from an acute cardiovascular care center
BMC Cardiovascular Disorders
December 2025
Bojti I.
ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes
Advances in Therapy
December 2025
Moreira R.O.
SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
Scientific Reports
December 2025
Huang B.
Ketone bodies in renal function and diabetic kidney disease
Journal of Nutritional Biochemistry
August 2025
Mechchate H.
Factors Associated with Response to SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes Mellitus †
Journal of Clinical Medicine
June 2025
Arora G.
Fournier’s Gangrene in an HIV-Positive Patient Using a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report
Journal of Wound Management and Research
February 2025
Yoon W.
Cardioprotective effectiveness of SGLT2 inhibitors in older diabetic women with early-stage breast cancer following anthracycline- and/or trastuzumab-based treatment
Therapeutic Advances in Medical Oncology
January-December 2025
Liu Y.S.
Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus
Frontiers in Endocrinology
2025
Yang H.
Recent updates and the state of the art of renal biochemistry
Renal Failure Insights from Nephrotic Syndrome to Systemic Renal Dynamics
1 January 2025
Ofori E.K.
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Biomedicines
September 2024
Caturano A.
Effect of SGLT2 inhibitors on kidney function of type 2 diabetes patients during Ramadan: A systematic review
Qatar Medical Journal
2024
Waheed M.A.
Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial)
Clinical Cardiology
January 2024
Mansouri M.H.
Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients
Scientific Reports
December 2023
Park S.
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Diabetologia
October 2023
Anson M.
How Low Can You Go? Safety and Efficacy of Sodium-Glucose Cotransporter Inhibitors in Decreased Renal Function
Journal of Pharmacy Practice
April 2023
Barvian C.K.
Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
Journal of Clinical Endocrinology and Metabolism
1 April 2023
Edwards K.
Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus: A meta-analysis of landmark renal and cardiovascular outcome trials
Indian Journal of Pharmacology
March 2023
Bose D.
Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment
Therapeutic Advances in Endocrinology and Metabolism
January-December 2023
Edwards K.
Metabolic effects of sodium-glucose co-transporter 2 inhibitor
Clinical Endocrinology and Endocrine Surgery
26 December 2022
Kedyk A.V.
Prevalence of Bacterial Urinary Tract Infection Among Patients with Type 2 Diabetes Mellitus on Sodium-Glucose Cotransporter-2 Inhibitors: A Prospective Real-World Setting Study
Journal of the Asean Federation of Endocrine Societies
November 2022
Ferwani P.
Sodium glucose Co-Transporter-2
Natural Products for Treatment of Metabolic Syndrome
12 October 2022
Mehta S.
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Journal of Clinical and Translational Hepatology
September/october 2022
Koullias E.S.
Sodium-glucose Co-transporter-2 inhibitors (SGLT2I): A class of drugs with promising cardiorenal protective effects beyond glycemic control
Annals of Medicine and Surgery
September 2022
Zaawari A.
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
International Journal of Molecular Sciences
April-1 2022
Salvatore T.
Risk of genital and urinary tract infections associated with SGLT-2 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes mellitus: A retrospective cohort study in Korea
Pharmacology Research and Perspectives
February 2022
Yang H.
Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease
Journal of Cellular Physiology
February 2022
Ravindran S.
The Evaluation of Cardiovascular Risk in Diabetic Patients
European Pharmaceutical Journal
1 January 2022
Kosirova S.
Cost-effectiveness analysis of Dapagliflozin versus Canagliflozin in treatment of type 2 diabetes mellitus
Journal of Applied Pharmaceutical Science
2022
Krishnamoorthy S.G.
Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy
World Journal of Cardiology
26 December 2021
Nashawi M.
Analysis of post-marketing adverse drug reactions induced by dapagliflozin based upon OpenFDA
Chinese Journal of Hospital Pharmacy
30 October 2021
Lin Z.Q.
Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes
Kidney International Reports
August 2021
Liu H.
Diastolic dysfunction and impaired cardiac output reserve in dysmetabolic nonhuman primate with proteinuria
Journal of Diabetes and Its Complications
April 2021
Wikstrom J.
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2021
Wijarnpreecha K.
Effect of add-on therapy of dapagliflozin and empagliflozin on adipokines in type 2 diabetes mellitus
Journal of Endocrinology and Metabolism
2021
Shaheer A.
Clinical and demographic characteristics, management of patients with type 2 diabetes mellitus and vascular complications: analysis of the Ukrainian cohort of the DISCOVER Global Registry
Ukrainian Journal of Cardiology
2021
Parkhomenko O.M.
Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients
Journal of Diabetes Investigation
January 2021
Kashiwagi A.
Risk factors and pharmacological therapy in patients with vascular disease
Vascular Surgery A Clinical Guide to Decision Making
1 January 2021
Maiolino G.
Carbohydrate metabolism in chronic renal disease
Nutritional Management of Renal Disease Fourth Edition
1 January 2021
Adamczak M.
Dapagliflozin as an adjunct therapy to insulin in patients with type 1 diabetes mellitus: Efficacy and safety of this combination
Touchreviews in Endocrinology
2021
Jendle J.H.
A clinical study on the association of sodium-glucose cotransporter 2 inhibitors and acute kidney injury among diabetic chinese population
Diabetes Metabolic Syndrome and Obesity
2021
Shen L.
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
Diabetes Therapy
1 September 2020
Ramos M.
Diabetes mellitus: an important risk factor for peripheral vascular disease
Expert Review of Cardiovascular Therapy
3 March 2020
Giannopoulos S.
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
Diabetes Therapy
1 February 2020
Williams D.M.
Do we have enough evidence to support the use of SGLT2 inhibitors for MACE reduction in patients with advance kidney disease?
European Journal of Internal Medicine
December 2019
Doshi R.